Sort   by:  
 Page size 
UnknownABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer.
Not available
S-EPMC4673991 | biostudies-literature
UnknownEfficacy and safety of IV ferumoxytol for iron deficiency anemia in patients with cancer.
Not available
S-EPMC5724711 | biostudies-literature
UnknownSafety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study.
Not available
S-EPMC4725221 | biostudies-literature
UnknownEfficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron.
Not available
S-EPMC4223995 | biostudies-literature
UnknownRivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
Not available
S-EPMC7476843 | biostudies-literature
UnknownA first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.
Not available
S-EPMC5361694 | biostudies-literature
UnknownEvaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
Not available
S-EPMC4742634 | biostudies-literature
UnknownRivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Not available
S-EPMC6328370 | biostudies-literature
UnknownA randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Not available
S-EPMC4110463 | biostudies-literature
Sort   by:  
 Page size